17 results on '"Carolina Figueroa"'
Search Results
2. Utilidad de la monitorización terapéutica de infliximab en el manejo de la enfermedad inflamatoria intestinal
- Author
-
Daniela Simian, Daniela Fluxá, Patricio Ibáñez, Gonzalo Pizarro, Udo Kronberg, Rodrigo Quera, Carolina Figueroa, Jaime Lubascher, Mauricio Moreno, and Lilian Flores
- Subjects
medicine.medical_specialty ,Anticuerpos monoclonales ,Crohn disease ,business.industry ,Therapeutics ,General Medicine ,medicine.disease ,Ulcerative colitis ,Gastroenterology ,Infliximab ,Crohn Disease ,Internal medicine ,medicine ,Drug Monitoring ,business ,medicine.drug - Abstract
Background: Primary non-response and secondary loss of response (LOR) are significant problems of biological therapy for inflammatory bowel disease (IBD). Therapeutic drug monitoring (TDM) in IBD patients receiving these drugs can improve outcomes. Aim: To measure serum infliximab levels and anti-infliximab antibodies (ATI) in patients with IBD post-induction phase and during maintenance therapy assessing the clinical course of IBD. Patients and Methods: Prospective study of IBD patients receiving infliximab between July 2016-May 2017. Group-A included patients who received induction therapy while Group-B included patients who were in maintenance therapy. TDM was performed in serum samples collected at weeks-14 and 30 in Group-A and before the infliximab maintenance dose in Group-B. Clinical scores, fecal calprotectin and endoscopic score were also evaluated. Results: Of 14 patients in Group-A, 57% achieved endoscopic response. Median serum infliximab concentrations at week-14 and 30 were 2.65 AU/mL (0.23-32.58) and 2.3 AU/mL (0.3-16.8), respectively. Patients with mucosal healing had non-significantly higher median infliximab concentrations at week- 14, as compared to week 30 (median 3.2 vs 2.2 AU/ml, respectively, p 0.6). ATI >10 ug/mL were found in one and seven patients at week-14 and 30, respectively. At 52 weeks of follow-up, four patients (31%) had LOR. Group-B included 36 patients, 33% had LOR. Median serum concentrations of infliximab were 1.4 AU/mL (0.27-7.03). No significant differences in serum infliximab concentration were observed between patients in remission and those with inflammatory activity. Seventeen patients had ATI >10 ug/mL. Conclusions: Clinical algorithms using TDM might help to optimize the pharmacological therapy of IBD.
- Published
- 2018
3. Presencia de Escherichia coli intracelular en mucosa intestinal de pacientes con Enfermedad Inflamatoria Intestinal y su asociación con características clínicas y el uso de corticosteroides
- Author
-
Marcela A. Hermoso, Mauricio Olivares, Roberto Vidal, Rocío Gutiérrez, Rodrigo Quera, David Díaz-Jiménez, Marjorie De la Fuente, Carolina Figueroa, Isidora Chahuán, and Daniela Simian
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Eschericchia coli ,Colonoscopy ,Ulcerative ,medicine.disease_cause ,Gastroenterology ,Pathogenesis ,03 medical and health sciences ,Crohn Disease ,Gentamicin protection assay ,Intestinal mucosa ,Internal medicine ,Biopsy ,medicine ,Colitis ,Escherichia coli ,medicine.diagnostic_test ,business.industry ,Microbiota ,General Medicine ,medicine.disease ,Ulcerative colitis ,digestive system diseases ,030104 developmental biology ,Immunology ,business - Abstract
Background: Different strains of invasive Escherichia coli (E. coli), isolated from intestinal mucosa of patients, are related to the pathogenesis of inflammatory bowel diseases (IBD). Aim: To evaluate an association between intracellular E. coli and IBD; its clinical characteristics and use of steroids. Material and Methods: Sixty one patients with Crohn's disease and 83 with ulcerative colitis were studied. To determine the intracellular E. coli content, colonoscopy biopsies of these patients and 29 control subjects were processed using the gentamicin protection assay. Differences in the bacterial content between patient groups were evaluated using Mann-Whitney test, while the association between presence of E. coli with endoscopic activity, location/extension and use of corticosteroid as anti-inflammatory treatment were evaluated with Fisher's exact test or Chi-square test. Results: E. coli strains were detected in 36.1, 39.3 and 10.3% of patients with ulcerative colitis, Crohn's disease and controls, respectively. The number of bacteria per biopsy in Crohn's disease and ulcerative colitis was significantly higher than in controls (p < 0.01 between patients and controls). In ulcerative colitis, significant associations were found between the presence of bacteria and disease location and use of corticosteroids. In Crohn's disease, no association was found. Conclusions: IBD are associated with the presence of intracellular E. coli strains in the intestinal mucosa, suggesting an alteration in the microbiota or loss of integrity of the epithelial barrier. The association of intracellular E. coli with clinical features and the use of corticosteroids in ulcerative colitis suggests that different factors could promote colonization or proliferation of these bacteria.
- Published
- 2017
4. Experiencia local con natalizumab en pacientes con enfermedad de Crohn refractaria a anti-TNF: Casos clínicos
- Author
-
Daniela Fluxá, Daniela Simian, Lilian Flores, Udo Kronberg, Jaime Lubascher, Patricio Ibáñez, Rodrigo Quera, Paola Toche, Carolina Figueroa, and Gonzalo Pizarro
- Subjects
medicine.drug_class ,business.industry ,Natalizumab ,Inflammatory Bowel Disease ,JC virus ,General Medicine ,medicine.disease_cause ,Monoclonal antibody ,medicine.disease ,Inflammatory bowel disease ,Infliximab ,Biological Therapy ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,Refractory ,Immunology ,medicine ,Tumor necrosis factor alpha ,030212 general & internal medicine ,Complication ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Anti-tumor necrosis factor-α (TNF) agents have dramatically changed the management of Crohns Disease (CD). However, a significant number of these patients do not respond at all or cease to respond to antibodies against TNF. In this clinical situation, the options include intensification of anti-TNF therapy by either increasing the dose or by shortening the administration interval, the use of a second anti-TNF or medications with a different mechanism of action. Among the later, Natalizumab, a humanized IgG4 monoclonal antibody against α4β1 and α4β7 integrins, is safe and effective in inducing and maintaining remission in active CD patients refractory to anti-TNF. In spite of this, Natalizumab use has been limited because of an increased risk of progressive multifocal leukoencephalophaty which results from reactivation of the John Cunningham (JC) virus. However, the presence of antibodies against JC virus in serum can be used to reduce the risk for this complication. We report three patients with Crohns disease refractory to treatment with infliximab, who responded successfully to the use of Natalizumab.
- Published
- 2017
5. [Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease]
- Author
-
Rodrigo, Quera, Mauricio, Moreno, Daniela, Simian, Patricio, Ibáñez, Jaime, Lubascher, Carolina, Figueroa, Lilian, Flores, Udo, Kronberg, Gonzalo, Pizarro, and Daniela, Fluxá
- Subjects
Adult ,Male ,Adolescent ,Reproducibility of Results ,Enzyme-Linked Immunosorbent Assay ,Colonoscopy ,Middle Aged ,Severity of Illness Index ,Infliximab ,Statistics, Nonparametric ,Young Adult ,Treatment Outcome ,Crohn Disease ,Gastrointestinal Agents ,Reference Values ,Humans ,Colitis, Ulcerative ,Female ,Prospective Studies ,Drug Monitoring ,Child - Published
- 2018
6. [Environmental risk factors in the development and evolution of inflammatory bowel disease]
- Author
-
Noelia E, Meligrana, Rodrigo, Quera, Carolina, Figueroa, Patricio, Ibáñez, Jaime, Lubascher, Udo, Kronberg, Lilian, Flores, and Daniela, Simian
- Subjects
Risk Factors ,Probiotics ,Tobacco ,Humans ,Environmental Exposure ,Obesity ,Protective Factors ,Inflammatory Bowel Diseases ,Diet - Abstract
Environmental factors may influence the development of Inflammatory Bowel Disease and modify its natural history. The objective of this review is to evaluate current evidence about environmental factors associated with the disease. A better knowledge about the pathogenesis of the disease can lead to better treatment strategies and suggestions to prevent the disease.
- Published
- 2018
7. Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
- Author
-
Javier Brahm, Carolina Figueroa, Jaime Lubascher, Raúl Acuña, Lital Meyer, Rodrigo Quera, G Silva, and Daniela Simian
- Subjects
medicine.medical_specialty ,Univariate analysis ,Leukopenia ,business.industry ,Inflammatory Bowel Disease ,Azathioprine ,General Medicine ,Colitis ,medicine.disease ,Gastroenterology ,Inflammatory bowel disease ,Ulcerative colitis ,Pancytopenia ,Drug-related side effects and adverse reactions ,digestive system diseases ,Surgery ,Discontinuation ,Crohn Disease ,Internal medicine ,medicine ,medicine.symptom ,business ,Adverse effect ,ulcerative ,medicine.drug - Abstract
Background: The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE). Aim: To report AE of different prescriptions used for the treatment of IBD. Material and Methods: Analysis of a registry of patients with IBD held at a private clinic from 1976 to 2013. All used medications, the occurrence and severity of AE were recorded. Results: The records of 346 patients aged 16 to 86 years, 74% with ulcerative colitis, were analyzed. The most commonly type of medications prescribed were 5-aminosalicylates (5-ASAs) in 329 patients (92%), followed by adrenal steroids in 218 (61%). Forty nine AE were recorded in the same number of patents (14%). These were more common in patients with Crohn disease (n = 19, 21%). An univariate analysis, demonstrated that extra-intestinal manifestations, hospitalizations secondary to IBD crisis, requirement of surgery and treatment with steroids, immunosuppressants or biologic agents were significantly associated with the presence of AE. AEs were more common with immunosuppressants, followed by 5-ASAs and steroids. Discontinuation of therapy was required in 79, 100 and 43% of patients taking these medications, respectively. Twenty percent of AEs were severe. Leukopenia and pancytopenia along with alopecia were the most common AEs attributable to azathioprine. Conclusions: The occurrence of AEs in patients with IBD is uncommon. Even inmunosuppressants or biologic agents have a low rate of AE and most of them mild.
- Published
- 2015
8. [Acute severe ulcerative colitis treated with accelerated infliximab induction. Case report]
- Author
-
Daniela, Fluxá, Lilian, Flores, Udo, Kronberg, Mauricio, Moreno, Carolina, Figueroa, Patricio, Ibáñez, Jaime, Lubascher, Daniela, Simian, and Rodrigo, Quera
- Subjects
Adult ,Feces ,Treatment Outcome ,Gastrointestinal Agents ,Biopsy ,Acute Disease ,Humans ,Colitis, Ulcerative ,Female ,Colonoscopy ,Leukocyte L1 Antigen Complex ,Infliximab - Abstract
Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerative colitis (UC) is recommended in the case of severe disease refractory to corticosteroids, once that superimposed bacterial or viral infections (such as cytomegalovirus or Clostridium difficile) have been excluded. However, conventional weight-based regimens of infliximab might be insufficient for patients with ASUC. Accelerated infliximab induction regimen may increase its serum concentration levels and efficacy by reducing early colectomy rates in these patients. We report a 34 year old female presenting with an ASUC. She was initially treated with hydrocortisone 300 mg/day and mesalazine enemas 4 g/day with an unfavorable clinical response. At the fifth day of therapy, an accelerated induction therapy with infliximab was started in doses of 10 mg/kg at weeks 0, 1 and 4. After the second dose, there was a favorable response with reduction of abdominal pain, stool frequency and hematochezia. She was discharged with prednisone and azathioprine. After a year of starting infliximab, the patient remains in clinical remission.
- Published
- 2017
9. [Presence of intracellular Escherichia coli in patients with inflammatory bowel disease]
- Author
-
Marjorie, De La Fuente, Isidora, Chahuán, RocÍo, Gutiérrez, David, Díaz-Jiménez, Mauricio, Olivares, Roberto, Vidal, Daniela, Simian, Carolina, Figueroa, Rodrigo, Quera, and Marcela A, Hermoso
- Subjects
Adult ,Aged, 80 and over ,Male ,Adolescent ,Anti-Inflammatory Agents ,Colony Count, Microbial ,Middle Aged ,Statistics, Nonparametric ,Young Adult ,Crohn Disease ,Adrenal Cortex Hormones ,Reference Values ,Case-Control Studies ,Escherichia coli ,Humans ,Colitis, Ulcerative ,Female ,Prospective Studies ,Intestinal Mucosa ,Aged - Abstract
Different strains of invasive Escherichia coli (E. coli), isolated from intestinal mucosa of patients, are related to the pathogenesis of inflammatory bowel diseases (IBD).To evaluate an association between intracellular E. coli and IBD; its clinical characteristics and use of steroids.Sixty one patients with Crohn's disease and 83 with ulcerative colitis were studied. To determine the intracellular E. coli content, colonoscopy biopsies of these patients and 29 control subjects were processed using the gentamicin protection assay. Differences in the bacterial content between patient groups were evaluated using Mann-Whitney test, while the association between presence of E. coli with endoscopic activity, location/extension and use of corticosteroid as anti-inflammatory treatment were evaluated with Fisher's exact test or Chi-square test.E. coli strains were detected in 36.1, 39.3 and 10.3% of patients with ulcerative colitis, Crohn's disease and controls, respectively. The number of bacteria per biopsy in Crohn's disease and ulcerative colitis was significantly higher than in controls (p0.01 between patients and controls). In ulcerative colitis, significant associations were found between the presence of bacteria and disease location and use of corticosteroids. In Crohn's disease, no association was found.IBD are associated with the presence of intracellular E. coli strains in the intestinal mucosa, suggesting an alteration in the microbiota or loss of integrity of the epithelial barrier. The association of intracellular E. coli with clinical features and the use of corticosteroids in ulcerative colitis suggests that different factors could promote colonization or proliferation of these bacteria.
- Published
- 2017
10. Enfermedad inflamatoria intestinal a partir de una experiencia local: Experience in 316 patients
- Author
-
Rodrigo Quera, Jorge Larach, Camila Estay, Javier Brahm, G Silva, Carolina Figueroa, Claudio Wainstein, Daniela Simian, Jaime Lubascher, Udo Kronberg, Andrés Larach, Raúl Acuña, and Francisco López-Köstner
- Subjects
medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,General Medicine ,Disease ,medicine.disease ,Ulcerative colitis ,Inflammatory bowel disease ,digestive system diseases ,Surgery ,Concomitant ,Internal medicine ,Epidemiology ,Medicine ,In patient ,business ,Pathological - Abstract
Background: The incidence and prevalence of Inflammatory Bowel Disease (IBD) has increased. Aim: To determine demographic and clinical characteristics of patients with IBD in a Chilean private hospital. Patients and methods: Review of a prospective registry of patients with IBD, started on 2012. It includes clinical, imaging, endoscopical and pathological information of patients. Results: Data of 316 patients with IBD, aged 16 to 86 years (56% females), were analyzed. Ulcerative Colitis (UC), Crohn´s and non-classifiable IBD were diagnosed in 230, 77 and 9 patients, respectively. The disease was diagnosed in 82% of patients in the period between 2002 and 2012. There was a peak in the diagnosis of both UC and CD between 20 and 39 years of age, without gender differences. The disease switched from UC to CD in six patients. In four, there was a change in disease behavior. Thirty eight patients were treated with biological therapy. The median lapse between the diagnosis and the use of biological therapy was 1 year in patients diagnosed after 2007, compared with 5.5 years among those patients diagnosed before 2007 (p=0.001). There was a trend towards a higher requirement of surgery until 2006. Posteriorly there was a stabilization of the requirement, concomitant with the incorporation of biological therapy. Conclusions: An adequate registry of IBD patients is necessary to improve demographic and clinical characteristics. A national registry is needed to assess the epidemiological changes of IBD in Chile.
- Published
- 2014
11. [Prognostic factors of ulcerative colitis at the moment of diagnosis]
- Author
-
Gonzalo, Pizarro, Rodrigo, Quera, and Carolina, Figueroa
- Subjects
Male ,Sex Factors ,Risk Factors ,Age Factors ,Humans ,Colitis, Ulcerative ,Female ,Prognosis ,Risk Assessment ,Severity of Illness Index ,Biomarkers ,Colectomy - Abstract
The clinical presentation of ulcerative colitis at the moment of diagnosis is variable, and its clinical course is difficult to predict. It can range from a quiescent to a refractory chronic course that may require hospitalization and surgical procedures. It can also have complications such as colorectal cancer. In this review we discuss the role of demographic, clinical, endoscopic, histological and associated factors, which can help to predict the clinical course of the disease at the moment of diagnosis, and to individualize therapy according to this clinical risk. Accurate identification of patients with a newly diagnosed ulcerative colitis who are at high risk of an unfavorable outcome is still a challenge. However, an effective evaluation allows an early diagnosis, a timely and effective treatment.
- Published
- 2016
12. [Development of malignant tumors in patients with inflammatory bowel disease]
- Author
-
Lital, Meyer, Daniela, Simian, Udo, Kronberg, Camila, Estay, Jaime, Lubascher, Carolina, Figueroa, and Rodrigo, Quera
- Subjects
Adult ,Aged, 80 and over ,Male ,Adolescent ,Middle Aged ,Inflammatory Bowel Diseases ,Biological Therapy ,Cohort Studies ,Young Adult ,Crohn Disease ,Risk Factors ,Humans ,Colitis, Ulcerative ,Female ,Chile ,Colorectal Neoplasms ,Immunosuppressive Agents ,Aged - Abstract
The chronic inflammation of the intestinal mucosa, the extra-intestinal manifestations of the disease and the immunosuppressive treatment of inflammatory bowel disease may increase cancer risk.To report the demographic and clinical features of patients with IBD who developed a malignant tumor.Retrospective analysis of an IBD patient registry of a private clinic, diagnosed between 1976 and 2014.437 subjects were included, aged 15-88 years (58% women). Seventy two percent of patients had ulcerative colitis. The median time of follow up was 6 years. Ten patients (2.3%) developed a malignant tumor. In four, the tumor could be related to IBD (two colorectal cancers, one cholangiocarcinoma and one chronic myeloid leukemia (CML)). Two of 45 patients treated with biological therapy developed a tumor (CML and hypernephroma). Three of 170 patients on immunosuppressive treatment developed tumors. Only one had a tumor possibly related with the use of azathioprine (non-melanoma skin cancer). In only two patients, the treatment was changed at the time of their cancer diagnosis, from immunosuppressive medications to mesalamine.Only a small proportion of these patients with IBD developed a malignant tumor. The treatment of IBD has to be determined by the severity of the disease and not by the fear of developing a neoplasia. Following recommendations is fundamental to decrease the possibility of developing this complication.
- Published
- 2014
13. [Adverse events associated with the treatment of inflammatory bowel disease]
- Author
-
Lital, Meyer, Daniela, Simian, Jaime, Lubascher, Raúl, Acuña, Carolina, Figueroa, Guillermo, Silva, Javier, Brahm, and Rodrigo, Quera
- Subjects
Adult ,Aged, 80 and over ,Male ,Adolescent ,Anti-Inflammatory Agents, Non-Steroidal ,Antibodies, Monoclonal ,Middle Aged ,Inflammatory Bowel Diseases ,Young Adult ,Cross-Sectional Studies ,Crohn Disease ,Risk Factors ,Humans ,Colitis, Ulcerative ,Female ,Immunosuppressive Agents ,Aged ,Retrospective Studies - Abstract
The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE).To report AE of different prescriptions used for the treatment of IBD.Analysis of a registry of patients with IBD held at a private clinic from 1976 to 2013. All used medications, the occurrence and severity of AE were recorded.The records of 346 patients aged 16 to 86 years, 74% with ulcerative colitis, were analyzed. The most commonly type of medications prescribed were 5-aminosalicylates (5-ASAs) in 329 patients (92%), followed by adrenal steroids in 218 (61%). Forty nine AE were recorded in the same number of patents (14%). These were more common in patients with Crohn disease (n = 19, 21%). An univariate analysis, demonstrated that extra-intestinal manifestations, hospitalizations secondary to IBD crisis, requirement of surgery and treatment with steroids, immunosuppressants or biologic agents were significantly associated with the presence of AE. AEs were more common with immunosuppressants, followed by 5-ASAs and steroids. Discontinuation of therapy was required in 79, 100 and 43% of patients taking these medications, respectively. Twenty percent of AEs were severe. Leukopenia and pancytopenia along with alopecia were the most common AEs attributable to azathioprine.The occurrence of AEs in patients with IBD is uncommon. Even inmunosuppressants or biologic agents have a low rate of AE and most of them mild.
- Published
- 2014
14. [Inflammatory bowel disease. Experience in 316 patients]
- Author
-
Daniela, Simian, Camila, Estay, Jaime, Lubascher, Raúl, Acuña, Udo, Kronberg, Carolina, Figueroa, Javier, Brahm, Guillermo, Silva, Francisco, López-Köstner, Claudio, Wainstein, Andrés, Larach, Jorge, Larach, and Rodrigo, Quera
- Subjects
Adult ,Aged, 80 and over ,Male ,Adolescent ,Middle Aged ,Inflammatory Bowel Diseases ,Severity of Illness Index ,Cohort Studies ,Young Adult ,Age Distribution ,Humans ,Female ,Chile ,Aged - Abstract
The incidence and prevalence of Inflammatory Bowel Disease (IBD) has increased.To determine demographic and clinical characteristics of patients with IBD in a Chilean private hospital.Review of a prospective registry of patients with IBD, started on 2012. It includes clinical, imaging, endoscopical and pathological information of patients.Data of 316 patients with IBD, aged 16 to 86 years (56% females), were analyzed. Ulcerative Colitis (UC), Crohn´s and non-classifiable IBD were diagnosed in 230, 77 and 9 patients, respectively. The disease was diagnosed in 82% of patients in the period between 2002 and 2012. There was a peak in the diagnosis of both UC and CD between 20 and 39 years of age, without gender differences. The disease switched from UC to CD in six patients. In four, there was a change in disease behavior. Thirty eight patients were treated with biological therapy. The median lapse between the diagnosis and the use of biological therapy was 1 year in patients diagnosed after 2007, compared with 5.5 years among those patients diagnosed before 2007 (p = 0.001). There was a trend towards a higher requirement of surgery until 2006. Subsequently there was a stabilization of the requirement, concomitant with the incorporation of biological therapy.An adequate registry of IBD patients is necessary to improve demographic and clinical characteristics. A national registry is needed to assess the epidemiological changes of IBD in Chile.
- Published
- 2014
15. [Inflammatory bowel diseases: an immunological approach]
- Author
-
Sofía E, Sepúlveda, Caroll J, Beltrán, Alexis, Peralta, Paola, Rivas, Néstor, Rojas, Carolina, Figueroa, Rodrigo, Quera, and Marcela A, Hermoso
- Subjects
Diagnosis, Differential ,Toll-Like Receptor 4 ,Polymorphism, Genetic ,Crohn Disease ,Interleukins ,Nod2 Signaling Adaptor Protein ,Humans ,Colitis, Ulcerative ,Genetic Predisposition to Disease ,GATA3 Transcription Factor ,Inflammatory Bowel Diseases - Abstract
Inflammatory bowel diseases (IBD) are inflammatory diseases with a multifactorial component that involve the intestinal tract. The two relevant IBD syndromes are Crohn's disease (CD) and ulcerative colitis (UC). One factor involved in IBD development is a genetic predisposition, associated to NOD2/CARD15 and Toll-like receptor 4 (TLR4) polymorphisms that might favor infectious enterocolitis that is possibly associated to the development of IBD. The identification of specific immunologic alterations in IBD and their relationship to the etiology of the disease is a relevant research topic. The role of intra and extracellular molecules, such as transcription factors and cytokines that are involved in the inflammatory response, needs to be understood. The relevance of immunologic molecules that might drive the immune response to a T helper (Th) 1, Th 2 or the recently described Th 17 phenotype, has been demonstrated in animal models and clinical studies with IBD patients. CD and UC predominantly behave with a Th 1 and Th 2 immune phenotype, respectively. Recently, an association between CD and Th 17 has been reported. The knowledge acquired from immunologic and molecular research will help to develop accurate diagnostic methods and efficient therapies.
- Published
- 2008
16. Enfermedad inflamatoria intestinal: Una mirada inmunológica
- Author
-
Marcela A. Hermoso, Rodrigo Quera, Néstor Rojas, Paola Rivas, Alexis Peralta, Sofía E. Sepúlveda, Carolina Figueroa, and Caroll J. Beltrán
- Subjects
business.industry ,Nod2 signaling adaptor protein ,Crohn disease ,T-Lymphocytes, Helper-Inducer ,General Medicine ,Disease ,Inflammatory bowel diseases ,medicine.disease ,Infectious Enterocolitis ,Ulcerative colitis ,digestive system diseases ,Colitis, ulcerative ,Immune system ,NOD2 ,Immunology ,TLR4 ,Genetic predisposition ,medicine ,Colitis ,business - Abstract
Inflammatory bowel diseases (IBD) are inflammatory diseases with a multifactorial component that involve the intestinal tract. The two relevant IBD syndromes are Crohn's disease (CD) and ulcerative colitis (UC). One factor involved in IBD development is a genetic predisposition, associated to NOD2/CARD15 and Toll-like receptor 4 (TLR4) polymorphisms that might favor infectious enterocolitis that is possibly associated to the development of IBD. The identification of specific immunologic alterations in IBD and their relationship to the etiology of the disease is a relevant research topic. The role of intra and extracellular molecules, such as transcription factors and cytokines that are involved in the inflammatory response, needs to be understood. The relevance of immunologic molecules that might drive the immune response to a T helper (Th) 1, Th 2 or the recently described Th 17 phenotype, has been demonstrated in animal models and clinical studies with IBD patients. CD and UC predominantly behave with a Th 1 and Th 2 immune phenotype, respectively. Recently, an association between CD and Th 17 has been reported. The knowledge acquired from immunologic and molecular research will help to develop accurate diagnostic methods and efficient therapies (Rev Med Chile 2008; 136: 367-75). (Key words: Colitis, ulcerative; Crohn disease; T-Lymphocytes, Helper-Inducer; Inflammatory bowel diseases; Nod2 signaling adaptor protein)
- Published
- 2008
17. [Inflammatory bowel disease: experience of two Chilean centers]
- Author
-
Carolina, Figueroa C, Rodrigo, Quera P, Jorge, Valenzuela E, and Christian, Jensen B
- Subjects
Adult ,Male ,Chi-Square Distribution ,Adolescent ,Age Factors ,Anti-Inflammatory Agents ,Middle Aged ,Inflammatory Bowel Diseases ,Sex Factors ,Crohn Disease ,Socioeconomic Factors ,Humans ,Colitis, Ulcerative ,Female ,Chile ,Aged ,Retrospective Studies - Abstract
The incidence of Inflammatory Bowel Disease (IBD) has increased, particularly in the developed world, and probably also in Chile.To report our experience with a large group of patients from two medical centers, Hospital Clinico de la Universidad de Chile (HCUCH) and Clinica Las Condes (CLC) and to characterize the clinical features of IBD in Chile.Retrospective review of 238 patients with IBD (age range 14-78 years, 143 women) treated at HCUCH and CLC between January 1990 and August 2002.One hundred eighty one patients had ulcerative colitis (UC) and 57 had Crohn's disease (CD), with an UC/CD ratio of 3.2/1. Forty eight percent of patients were aged between 20 and 39 years old and 69% were diagnosed after 1995. Patients from HCUCH had more severe disease, more complications and needed surgery more often.Clinical features of Chilean patients with IBD are similar to those of other countries. UC is more common than EC. There is a higher proportion of women with the disease. The severity of the disease was higher among HCUCH.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.